氨噻二唑（NSC 4728）用于晚期卵巢癌患者。妇科肿瘤学组的一项II期研究。
Aminothiadiazole (NSC 4728) in patients with advanced ovarian carcinoma. A phase II study of the Gynecologic Oncology Group.
作者信息
Asbury R F, Wilson J, Blessing J A, Buchsbaum H J, DiSaia P J
出版信息
Am J Clin Oncol. 1986 Aug;9(4):334-6. doi: 10.1097/00000421-198608000-00012.
Abstract
Thirty-two evaluable patients with advanced epithelial ovarian cancer were treated with aminothiadiazole at a dosage of 125 mg/m2 weekly. Two patients had partial responses, 12 had stable disease, 16 had increasing disease, and two were inevaluable for response. Aminothiadiazole used in this dosage and schedule has minimal activity in ovarian carcinoma patients previously treated.
摘要
32例可评估的晚期上皮性卵巢癌患者接受了氨噻二唑治疗，剂量为每周125mg/m²。2例患者部分缓解，12例病情稳定，16例病情进展，2例疗效不可评估。以该剂量和疗程使用的氨噻二唑对既往接受过治疗的卵巢癌患者活性极小。
Zotero 插件